Quick Takeaways
- PCSA - Processa Pharmaceuticals, Inc. has 14 insiders with reported activity on this page.
- Net insider value flow over the last year: +$103,130.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 14 Insiders of Processa Pharmaceuticals, Inc.
- Symbol
- PCSA on Nasdaq
- Location
- Vero Beach, FL
What Changed
- Buy value: $103,130; sell value: $0.
- Net share flow: +38,262.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$103,130.
Buys
$103,130
Shares: 38,262
Insiders: 9
Sells
$0
Shares: 0
Insiders: 0
Net
+$103,130
Shares: +38,262
Insiders: 9
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 38,262 | 0 | $103,130 | $0 | +$103,130 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Processa Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| David Young | Pres. Research & Development, Director | $87,127 | +$13,766 | +19% | Mixed | 30 Apr 2026 |
| Sian Bigora | Chief Development Officer | $68,745 | +$16,027 | +30% | Mixed | 30 Apr 2026 |
| Patrick Lin | Chief Business - Strategy Off | $64,388 | +$12,194 | +23% | Mixed | 30 Apr 2026 |
| James H. Stanker | Chief Financial Officer | $61,609 | Mixed | 05 Apr 2024 | ||
| Wendy Guy | Chief Administrative Officer | $60,888 | +$14,104 | +30% | Mixed | 30 Apr 2026 |
| George K. Ng | Chief Executive Officer, Director | $55,991 | +$16,360 | +41% | Mixed | 30 Apr 2026 |
| Robert Michael Floyd | Chief Operating Officer | $51,618 | Mixed | 09 Feb 2023 | ||
| Virgil Thompson | Director | $42,163 | Mixed | 27 Jun 2023 | ||
| Russell Skibsted | Chief Financial Officer | $23,359 | +$17,675 | +311% | Mixed | 30 Apr 2026 |
| Yorke Justin W. | Director | $11,248 | Mixed | 01 Oct 2025 | ||
| Khoso Baluch | Director | $5,893 | +$5,752 | +4079% | Filing P/S | 31 Mar 2026 |
| Geraldine Pannu | Director | $5,546 | +$5,253 | +1793% | Filing P/S | 31 Mar 2026 |
| James R. Neal | Director | $2,073 | +$2,000 | +2740% | Filing P/S | 31 Mar 2026 |
| Khalid Islam | Director | Mixed | 31 Mar 2022 |
Top shareholders of Processa Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Chiliz Group Ltd. |
13D/G
|
HX Entertainment Ltd |
13%
|
305,644
|
$959,722 | $0 | 13 Feb 2026 | |
| CVI Investments, Inc. |
13D/G
|
— |
9%
|
5,000,000
|
$959,500 | +$101,502 | 30 Sep 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
8.1%
|
200,000
|
$644,000 | $0 | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
2,644,376
|
$608,206 | +$475,127 | 30 Jun 2025 | |
| 3i, LP |
13D/G
|
— |
4.9%
|
1,681,944
|
$504,583 | $0 | 17 Jun 2025 | |
| David Young |
3/4/5
|
Pres. Research & Development, Director |
—
mixed-class rows
|
411,479
mixed-class rows
|
$87,127 | +$13,766 | 30 Apr 2026 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
1.3%
|
30,190
|
$86,947 | — | 31 Dec 2025 | |
| Sian Bigora |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
295,763
mixed-class rows
|
$68,745 | +$16,027 | 30 Apr 2026 | |
| VANGUARD GROUP INC |
13F
|
Company |
1%
|
23,586
|
$67,928 | — | 31 Dec 2025 | |
| Patrick Lin |
3/4/5
|
Chief Business - Strategy Off |
—
mixed-class rows
|
301,726
mixed-class rows
|
$64,388 | +$12,194 | 30 Apr 2026 | |
| James H. Stanker |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
36,029
mixed-class rows
|
$61,609 | — | 05 Apr 2024 | |
| Wendy Guy |
3/4/5
|
Chief Administrative Officer |
—
mixed-class rows
|
156,774
mixed-class rows
|
$60,888 | +$14,104 | 30 Apr 2026 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.84%
|
19,691
|
$56,000 | — | 31 Dec 2025 | |
| George K. Ng |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
1,165,101
mixed-class rows
|
$55,991 | +$16,360 | 30 Apr 2026 | |
| Robert Michael Floyd |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
172,061
|
$51,618 | — | 09 Feb 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.65%
|
15,323
|
$44,130 | — | 31 Dec 2025 | |
| Virgil Thompson |
3/4/5
|
Director |
—
mixed-class rows
|
241,907
mixed-class rows
|
$42,163 | — | 27 Jun 2023 | |
| UBS Group AG |
13F
|
Company |
0.54%
|
12,640
|
$36,403 | — | 31 Dec 2025 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
0.52%
|
12,323
|
$35,490 | — | 31 Dec 2025 | |
| Russell Skibsted |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
438,498
mixed-class rows
|
$23,359 | +$17,675 | 30 Apr 2026 | |
| Yorke Justin W. |
3/4/5
|
Director |
—
mixed-class rows
|
660,074
mixed-class rows
|
$11,248 | — | 01 Oct 2025 | |
| Khoso Baluch |
3/4/5
|
Director |
—
mixed-class rows
|
608,830
mixed-class rows
|
$5,893 | +$5,752 | 31 Mar 2026 | |
| Geraldine Pannu |
3/4/5
|
Director |
—
mixed-class rows
|
608,693
mixed-class rows
|
$5,546 | +$5,253 | 31 Mar 2026 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.06%
|
1,390
|
$4,003 | — | 31 Dec 2025 | |
| James R. Neal |
3/4/5
|
Director |
—
mixed-class rows
|
607,323
mixed-class rows
|
$2,073 | +$2,000 | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
18
|
$52 | — | 31 Dec 2025 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0%
|
7
|
$20 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
6
|
$17 | — | 31 Dec 2025 | |
| Khalid Islam |
3/4/5
|
Director |
—
class O/S missing
|
18,208
|
— | — | 31 Mar 2022 |
Recent Insider Transactions by Companies or Individuals for Processa Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Young | PCSA | Common Stock | Purchase | 14.1% | $4,589 | $2.69 | 1,706 | 13,813 | 30 Apr 2026 | Direct |
| Russell Skibsted | PCSA | Common Stock | Purchase | 50.8% | $5,891 | $2.69 | 2,190 | 6,498 | 30 Apr 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | 51.1% | $5,471 | $2.69 | 2,034 | 6,013 | 30 Apr 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Purchase | 32% | $4,065 | $2.69 | 1,511 | 6,236 | 30 Apr 2026 | Direct |
| Wendy Guy | PCSA | Common Stock | Purchase | 37.2% | $4,702 | $2.69 | 1,748 | 6,441 | 30 Apr 2026 | Direct |
| Sian Bigora | PCSA | Common Stock | Purchase | 36% | $5,342 | $2.69 | 1,986 | 7,496 | 30 Apr 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | 86.3% | $5,474 | $2.97 | 1,843 | 3,979 | 15 Apr 2026 | Direct |
| David Young | PCSA | Common Stock | Purchase | 14.6% | $4,589 | $2.97 | 1,545 | 12,107 | 15 Apr 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Purchase | 40.8% | $4,066 | $2.97 | 1,369 | 4,725 | 15 Apr 2026 | Direct |
| Wendy Guy | PCSA | Common Stock | Purchase | 50.9% | $4,702 | $2.97 | 1,583 | 4,693 | 15 Apr 2026 | Direct |
| Sian Bigora | PCSA | Common Stock | Purchase | 48.5% | $5,343 | $2.97 | 1,799 | 5,510 | 15 Apr 2026 | Direct |
| Russell Skibsted | PCSA | Common Stock | Purchase | 85.4% | $5,892 | $2.97 | 1,984 | 4,308 | 15 Apr 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | $5,415 | $2.54 | 2,136 | 2,136 | 31 Mar 2026 | Direct | |
| James R. Neal | PCSA | Common Stock | Purchase | 2720.7% | $2,000 | $2.54 | 789 | 818 | 31 Mar 2026 | Direct |
| David Young | PCSA | Common Stock | Purchase | 20.7% | $4,588 | $2.54 | 1,810 | 10,562 | 31 Mar 2026 | Direct |
| Russell Skibsted | PCSA | Common Stock | Purchase | $5,891 | $2.54 | 2,324 | 2,324 | 31 Mar 2026 | Direct | |
| Geraldine Pannu | PCSA | Common Stock | Purchase | 1786.2% | $5,253 | $2.54 | 2,072 | 2,188 | 31 Mar 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Purchase | 91.4% | $4,064 | $2.54 | 1,603 | 3,356 | 31 Mar 2026 | Direct |
| Wendy Guy | PCSA | Common Stock | Purchase | 147.6% | $4,700 | $2.54 | 1,854 | 3,110 | 31 Mar 2026 | Direct |
| Sian Bigora | PCSA | Common Stock | Purchase | 131.4% | $5,341 | $2.54 | 2,107 | 3,711 | 31 Mar 2026 | Direct |
| Khoso Baluch | PCSA | Common Stock | Purchase | 4051.8% | $5,752 | $2.54 | 2,269 | 2,325 | 31 Mar 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Options Exercise | 12.4% | 193 | 1,753 | 01 Jan 2026 | Direct | ||
| Patrick Lin | PCSA | Common Stock | Options Exercise | -100% | -193 | 0 | 01 Jan 2026 | Direct | ||
| Wendy Guy | PCSA | Common Stock | Options Exercise | 18.2% | 193 | 1,256 | 01 Jan 2026 | Direct | ||
| Wendy Guy | PCSA | Restricted Stock Units | Options Exercise | -100% | -193 | 0 | 01 Jan 2026 | Direct | ||
| Sian Bigora | PCSA | Common Stock | Options Exercise | 18.4% | 249 | 1,604 | 01 Jan 2026 | Direct | ||
| Sian Bigora | PCSA | Restricted Stock Units | Options Exercise | -100% | -249 | 0 | 01 Jan 2026 | Direct | ||
| David Young | PCSA | Common Stock | Options Exercise | 0.56% | 49 | 8,752 | 01 Jan 2026 | Direct | ||
| David Young | PCSA | Restricted Stock Units | Options Exercise | -100% | -49 | 0 | 01 Jan 2026 | Direct | ||
| James R. Neal | PCSA | Stock Options (Right to Buy) | Award | 300,000 | 300,000 | 01 Oct 2025 | Direct | |||
| James R. Neal | PCSA | Restricted Stock Units | Award | 100,000 | 100,000 | 01 Oct 2025 | Direct | |||
| Khoso Baluch | PCSA | Stock Options (Right to Buy) | Award | 300,000 | 300,000 | 01 Oct 2025 | Direct | |||
| Khoso Baluch | PCSA | Restricted Stock Units | Award | 100,000 | 100,000 | 01 Oct 2025 | Direct | |||
| Geraldine Pannu | PCSA | Stock Options (Right to Buy) | Award | 300,000 | 300,000 | 01 Oct 2025 | Direct | |||
| Geraldine Pannu | PCSA | Restricted Stock Units | Award | 100,000 | 100,000 | 01 Oct 2025 | Direct | |||
| Justin W. Yorke | PCSA | Stock Options (Right to Buy) | Award | 300,000 | 300,000 | 01 Oct 2025 | Direct | |||
| Justin W. Yorke | PCSA | Restricted Stock Units | Award | 100,000 | 100,000 | 01 Oct 2025 | Direct | |||
| Wendy Guy | PCSA | Stock Options (Right to Buy) | Award | 150,000 | 150,000 | 01 Oct 2025 | Direct | |||
| Wendy Guy | PCSA | Restricted Stock Units | Award | 50,000 | 50,000 | 01 Oct 2025 | Direct | |||
| Patrick Lin | PCSA | Stock Options (Right to Buy) | Award | 204,000 | 204,000 | 01 Oct 2025 | Direct | |||
| Patrick Lin | PCSA | Restricted Stock Units | Award | 68,000 | 68,000 | 01 Oct 2025 | Direct | |||
| Sian Bigora | PCSA | Stock Options (Right to Buy) | Award | 288,000 | 288,000 | 01 Oct 2025 | Direct | |||
| Sian Bigora | PCSA | Restricted Stock Units | Award | 96,000 | 96,000 | 01 Oct 2025 | Direct | |||
| Russell Skibsted | PCSA | Stock Options (Right to Buy) | Award | 324,000 | 324,000 | 01 Oct 2025 | Direct | |||
| Russell Skibsted | PCSA | Restricted Stock Units | Award | 108,000 | 108,000 | 01 Oct 2025 | Direct | |||
| David Young | PCSA | Stock Options (Right to Buy) | Award | 333,000 | 333,000 | 01 Oct 2025 | Direct | |||
| David Young | PCSA | Restricted Stock Units | Award | 111,000 | 111,000 | 01 Oct 2025 | Direct | |||
| George K. Ng | PCSA | Stock Options (Right to Buy) | Award | 768,000 | 768,000 | 01 Oct 2025 | Direct | |||
| George K. Ng | PCSA | Restricted Stock Units | Award | 256,000 | 256,000 | 01 Oct 2025 | Direct | |||
| Wendy Guy | PCSA | Restricted Stock Units | Award | 13094.8% | 1,366,046 | 1,376,478 | 24 Jul 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.